



MOUNT SINAI HOSPITAL  
CANCER CARE CENTER

2018 Cancer Program Outcomes

We are proud of the patients we serve and our outcomes in cancer care and treatment. Our physicians, nurses, pharmacists and support staff are fully committed to putting our knowledge, experience and compassion forward to ensure the best possible outcome for each patient. We understand our responsibility as the humble servants of those who seek our assistance.

## *Cancer Committee Chair's Report*



Pam Khosla, MD  
Chief, Department of Oncology/Hematology  
Cancer Committee Chair

Sinai's Cancer Program is accredited by Commission on cancer. This publication is our Public Reporting of Outcomes as outlined by the American College of Surgeons' Commission on Cancer's (COC) accreditation standards.

The Cancer Committee to review the quality of patient care using COC quality reporting tools appropriate to the patients who are treated by the program each year.

The most recent 2016 information is taken from the National Cancer Data Base as of June 17, 2019 shows that Mount Sinai Hospital continues to meet or exceeded all local and national bench marks for breast cancer care for the above performance.

With regards to colon cancer Mt Sinai meets the standard for lymph node removal however for starting chemotherapy within four months of diagnosis we had very few (7) cases analyzed. Within those cases two patients were not able to start chemotherapy within that timeframe due to social issues.

We have established an exemplary Supportive oncology program with support from The Coleman Foundation to screen for psychosocial distress issues and address management of same through an excellent navigation program personalized for each patient.

We remain committed to providing highest quality of comprehensive cancer care for our patients.

# Accountability and Quality Improvement Measures

The Cancer Registry at Mount Sinai Hospital's Cancer Center submits data annually to the National Cancer Data Base (NCDB). The data elements required for submission to NCDB are utilized by the Commission on Cancer in evaluating and assessing quality measures that have been developed to ensure patient-centered treatment outcomes. The quality measures are endorsed by the NQF (National Quality Forum).

## Breast Cancer

### Accountability Measure

Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer

Mount Sinai Hospital	100%
State of Illinois	94%
All CoC Commission on Cancer Approved Programs	92%

### Accountability Measure

Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer

Mount Sinai Hospital	100%
State of Illinois	95%
All CoC Commission on Cancer Approved Programs	84%

## Colon Cancer

### Accountability Measure

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer

Mount Sinai Hospital	94%
State of Illinois	94%
All CoC Commission on Cancer Approved Programs	93%

### Accountability Measure

Adjuvant chemotherapy is recommended, or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer

Mount Sinai Hospital	86%
State of Illinois	93%
All CoC Commission on Cancer Approved Programs	89%

## Accountability and Quality Improvement Measures



## **Compliance with NCCN Guidelines**

In 2018, a chart audit was conducted on Head and Neck cancer patients who were diagnosed between 2016 and 2017. A total of 30 patients were reviewed according to the National Comprehensive Cancer Network guidelines in the treatment of Head and Neck cancer.

## **Results of Data**

Random samples of 30 patients were assessed to determine if treatment met the NCCN guidelines for care of patients with Head and Neck cancer.

- The patients chosen were stage II-IV.
- An audit tool was developed and approved by Dr. Kassem based on the NCCN Head and Neck cancer version 2.2018

Based on this review patients with stage II-IV Head and Neck cancer were managed appropriately with chemotherapy and radiation according to NCCN guidelines.

